Cytokine Signalling Forum
Cours de FMC
Highlights from EULAR 2021
This programme is provided by the Cytokine Signalling Forum and and sponsored by Lilly.
Release date: 09 June 2021
Estimated time to complete activity: 1 hour
Compatible with all modern internet browsers and mobile devices
EDUCATIONAL OBJECTIVES
After completing this activity, the learner will:
- Understand the safety and efficacy data of JAK inhibitors in RA from EULAR 2021
- Be familiar to new data on difficult-to-treat RA, pain, patient reported outcomes, and the effects of JAKinibs on pain
- Understand any other key highlights on cytokine signaling agents from EULAR 2021
TARGET AUDIENCE
This activity is designed for rheumatologists, and other healthcare professionals involved in treating patients with inflammatory diseases.
PROGRAMME OVERVIEW
With the continued release of new treatment data on JAK inhibitors for the management of rheumatoid arthritis and other immune mediated inflammatory diseases, this activity will highlight the key research reported at the virtual EULAR 2021 annual conference. This session will feature the latest safety and efficacy data of JAK inhibitors, followed by discussions on pain in relation to clinical remission and patient reported outcomes.
In this activity, Highlights from EULAR 2021, international experts will discuss some of the key research from EULAR 2021 for healthcare professionals and rheumatologists. The content will be discussion based and will have a focus on rheumatoid arthritis.
DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.
| Module | Présentateur | Vidéo | Questions |
|---|---|---|---|
| Highlights from EULAR 2021 |
Professor Christopher Edwards
Honorary Chair of Clinical Rheumatology, Professor Christopher Edwards is Consultant Rheumatologist and Honorary Chair of Clinical Rheumatology, University Hospital Southampton NHS Foundation Trust within Medicine at the University of Southampton. He graduated with honors from King's College London and trained at the Hammersmith and St George's Hospitals in London. He was a registrar for Professor Graham Hughes at the St Thomas' Hospital lupus unit and then undertook a period of research as a lecturer at the Kennedy Institute of Rheumatology at Imperial College under the supervision of Professor Ravinder Maini. He moved to Southampton in 2001 after working for a year as a rheumatology consultant at Tan Tock Seng Hospital in Singapore.
Professor Edwards is a clinical rheumatologist with research interests and expertise in the epidemiology and treatment of inflammatory rheumatic diseases including rheumatoid arthritis, lupus, psoriatic arthritis and ankylosing spondylitis. He is a member of international committees working to produce guidelines for the best management of rheumatic diseases, leading a systematic review of guidelines for the use of radiology in the diagnosis and management of rheumatoid arthritis for EULAR. With expertise in the planning and delivery of trials in this area, including early stage trials, Professor Edwards has developed strong local and international partnerships with clinical and academic colleagues, centered on his role as clinical lead of the Southampton Musculoskeletal Research Unit. Professor Edwards also serves as Associate Editor for Rheumatology, and on the editorial board of Lupus.
Professor Janet Pope
Professor of Medicine in the Division of Rheumatology, Professor Pope is a Professor of Medicine in the Division of Rheumatology at the University of Western Ontario, Schulich School of Medicine, and Division Head in Rheumatology at St Joseph's Health Care in London, Ontario, Canada. She obtained her Masters degree in Public Health and Fellowship in Rheumatology from Boston University. She then completed a Canadian Arthritis Society Research Fellow in Scleroderma. She is a section editor of Arthritis & Rheumatology, and on the Editorial Boards of Journal of Rheumatology, Nature Reviews Rheumatology, Lancet Rheumatology, RMD Open. Her research includes epidemiologic studies in scleroderma, systemic lupus erythematosus (SLE) and RA, including outcome measurements, clinical trials and disease manifestations. She has published over 500 peer-reviewed articles, 15 chapters, 600 abstracts, and several Cochrane meta-analysis reviews.
Professor Bernard Combe
Professor of Rheumatology at Montpellier University, France, Bernard Combe is Professor of Rheumatology at Montpellier University, France, and Head of the Bone and Joint Department at Montpellier University Hospital. He completed his medical education at Montpellier University and was subsequently awarded a research fellowship in clinical immunology at the University of Texas, San Antonio, USA. Professor Combe was elected member of the National Board of Universities (Rheumatology) from 1994–2000 and again from 2006, as well as being president from 2010–2013. He is an active member of numerous EULAR and ACR task forces. Professor Combe is Editor-in-Chief of RMD Open and of La Lettre du Rhumatologue. In addition, he is a member of the editorial boards of Annals of Rheumatic Diseases, Arthritis and Rheumatism and Joint Bone Spine. He has co-authored more than 315 articles published in international peer-reviewed journals and has been a coordinator or main investigator in 131 clinical trials. |
68:28 | 0 |
Date de préparation: 09 June 2021